Seroprevalence of SARS-CoV-2 antibodies in children - A prospective multicentre cohort study

Waterfield, Thomas; Watson, Chris; Moore, Robert K.; Ferris, Kathryn; Tonry, Claire; Watt, Alison; McGinn, Claire; Foster, Steven; Evans, Jennifer; Lyttle, Mark D; Ahmad, Shazaad; Ladhani, Shamez; Corr, Michael; McFetridge, Lisa; Mitchell, Hannah; Brown, Kevin E.; Amirthalingam, G; Maney, Julie-Ann; Christie, Sharon

doi:10.1101/2020.08.31.20183095

Cited by 27 publications

(22 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…• Representative samples from studies of England, France, Ireland, Italy, Netherlands, Portugal, Spain, Geneva (Switzerland), and four U.S. locations (Atlanta, Indiana, New York, and Salt Lake City). [3,13,19,[108][109][110][111][112][113][114][115][116][117] • Convenience samples from studies of Belgium, Sweden, Ontario (Canada), and eight U.S. locations (Connecticut, Louisiana, Miami, Minneapolis, Missouri, Philadelphia, San Francisco, and Seattle). [18,[118][119][120] • Comprehensive tracing programs for Australia, Iceland, Korea, Lithuania, and New Zealand.…”

Section: Resultsmentioning

confidence: 99%

Assessing the Age Specificity of Infection Fatality Rates for COVID-19: Systematic Review, Meta-Analysis, and Public Policy Implications

Levin

Hanage

Owusu‐Boaitey

et al. 2020

Preprint

141

View full text Add to dashboard Cite

This paper assesses the age specificity of the infection fatality rate (IFR) for COVID-19. Our benchmark meta-regression synthesizes the age-specific IFRs from six recent large-scale seroprevalence studies conducted in Belgium, Geneva, Indiana, New York, Spain, and Sweden. The estimated IFR is close to zero for children and younger adults but rises exponentially with age, reaching about 0.3 percent for ages 50-59, 1.3 percent for ages 60-69, 4.6 percent for ages 70-79, and 25 percent for ages 80 and above. We compare those predictions to the age-specific IFRs implied by recent seroprevalence estimates for nine other U.S. locations, three smale-scale studies, and three countries (Iceland, New Zealand, and Republic of Korea) that have engaged in comprehensive tracking and tracing of COVID-19 infections. We also review seroprevalence studies of 32 other locations whose design was not well-suited for estimating age-specific IFRs. Our findings indicate that COVID-19 is not just dangerous for the elderly and infirm but also for healthy middle-aged adults, for whom the fatality rate is more than 50 times greater than the risk of dying in an automobile accident. Consequently, the overall IFR for a given location is intrinsically linked to the age-specific pattern of infections. In a scenario where the U.S. infection rate reaches 20 percent, our analysis indicates that protecting vulnerable age groups could prevent more than 200,000 deaths.

show abstract

Section: Resultsmentioning

confidence: 99%

Assessing the Age Specificity of Infection Fatality Rates for COVID-19: Systematic Review, Meta-Analysis, and Public Policy Implications

Levin

Hanage

Owusu‐Boaitey

et al. 2020

Preprint

141

View full text Add to dashboard Cite

show abstract

“…• Representative samples from studies of England, Ireland, Italy, Netherlands, Portugal, Spain, Geneva (Switzerland), and four U.S. locations (Atlanta, Indiana, New York, and Salt Lake City). [3,13,19,[105][106][107][108][109][110][111][112][113] • Convenience samples from studies of Belgium, France, Sweden, Ontario (Canada), and eight U.S. locations (Connecticut, Louisiana, Miami, Minneapolis, Missouri, Philadelphia, San Francisco, and Seattle). [18,[114][115][116] • Comprehensive tracing programs for Australia, Iceland, Korea, Lithuania, and New Zealand.…”

Section: Resultsmentioning

confidence: 99%

Assessing the Age Specificity of Infection Fatality Rates for COVID-19: Systematic Review, Meta-analysis, & Public Policy Implications

Levin¹,

Hanage²,

Owusu‐Boaitey³

et al. 2020

104

129

View full text Add to dashboard Cite

To assess age-specific infection fatality rates (IFRs) for COVID-19, we have conducted a systematic review of seroprevalence studies as well as countries with comprehensive tracing programs. Age-specific IFRs were computed using the prevalence data in conjunction with reported fatalities four weeks after the midpoint date of each study, reflecting typical lags in fatalities and reporting. Using metaregression procedures, we find a highly significant log-linear relationship between age and IFR for COVID-19. The estimated age-specific IFRs are very low for children and younger adults but increase progressively to 0.4% at age 55, 1.3% at age 65, 4.2% at age 75, and 14% at age 85. About 90% of the geographical variation in population IFR is explained by differences in age composition of the population and age-specific prevalence. These results indicate that COVID-19 is hazardous not only for the elderly but also for middle-aged adults. Moreover, the population IFR for COVID-19 should not be viewed as a fixed parameter but as intrinsically linked to the age-specific pattern of infections. Consequently, public health measures to protect vulnerable age groups could substantially decrease total deaths.

show abstract

“…4 This almost certainly represented large numbers of children attending school with mild fevers and URI symptoms, caused by a variety of common circulating winter viruses Yet these URI symptoms led to many CYP being asked to quarantine or be tested for SARS-CoV-2 before returning to school. 5 Moreover there has been some uncertainty about which symptoms indicate likely COVID-19 in children and young people (CYP), as some recent studies have suggested that other symptoms such as gastrointestinal symptoms 6 or fatigue 6 7 may be common in CYP with COVID-19.…”

Section: Introductionmentioning

confidence: 99%

Systematic review of reviews of symptoms and signs of COVID-19 in children and adolescents

Viner

Hudson

Ashe

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective To undertake a systematic review of reviews of the prevalence of symptoms and signs of COVID-19 in those aged under 20 years? Design Narrative systematic review of reviews. PubMed, medRxiv, Europe PMC and COVID-19 Living Evidence Database were searched on 9 October 2020. Setting All settings, including hospitalised and community settings. Patients CYP under age 20 years with laboratory-proven COVID-19. Study review, data extraction and quality Potentially eligible articles were reviewed on title and abstract by one reviewer. Quality was assessed using the modified AMSTARS criteria and data were extracted from included studies by two reviewers. Main outcome measures Prevalence of symptoms and signs of COVID-19 Results 1325 studies were identified and 18 reviews were included. Eight were high quality, 7 medium and 3 low quality. All reviews were dominated by studies of hospitalised children. The proportion who were asymptomatic ranged from 14.6 to 42%. Fever and cough were the commonest symptoms; proportions with fever ranged from 46 to 64.2% and with cough from 32 to 55.9%. All other symptoms or signs including rhinorrhoea, sore throat, headache, fatigue/myalgia and gastrointestinal symptoms including diarrhoea and vomiting are infrequent, occurring in less than 10-20%. Conclusions Fever and cough are the most common symptoms in CYP with COVID-19, with other symptoms infrequent. Further research on symptoms in community samples are needed to inform pragmatic identification and testing programmes for CYP.

show abstract

Seroprevalence of SARS-CoV-2 antibodies in children - A prospective multicentre cohort study

Cited by 27 publications

References 27 publications

Assessing the Age Specificity of Infection Fatality Rates for COVID-19: Systematic Review, Meta-Analysis, and Public Policy Implications

Assessing the Age Specificity of Infection Fatality Rates for COVID-19: Systematic Review, Meta-Analysis, and Public Policy Implications

Assessing the Age Specificity of Infection Fatality Rates for COVID-19: Systematic Review, Meta-analysis, & Public Policy Implications

Systematic review of reviews of symptoms and signs of COVID-19 in children and adolescents

Contact Info

Product

Resources

About